Epicrispr Biotechnologies closed a $90M series C on Tuesday to advance its epigenetic therapy toward pivotal studies in facioscapulohumeral muscular dystrophy (FSHD)
CEO Amber Salzman discusses the benefit of the raise, and contrasts the funding environment in biotech today versus previous years. Plus, she describes the unmet need in FSHD and how AI has already been helping the company understand the patient experience in its current clinical trial.
3 days ago
LifeMine Therapeutics announced a $263M raise today to help accelerate the development of its novel calcineurin activation inhibitor that aims to radically change the profile of organ transplants
Co-Founder, President & CEO Greg Verdine describes the toxicity issues associated with the immuosupressive drugs that transplant recipients currently receive, and explains how LIFE-001 is different. Plus, given how the therapy is designed to safely prevent T-cell activation and proliferation, there could also ultimately be an autoimmune use case as well.
Aug 6
From NYSE: Noetik has been building a large database from patient tumor samples to use AI to help understand which patients are more likely to respond to medicines in the future
CEO Ron Alfa describes the platform's design, and walks us through partnerships with Agenus and GSK.
Jul 23
From NYSE: Alloy Therapeutics, which has a service provider model of helping other companies develop therapies, recently crossed the $1B valuation mark on their series E and is now fully integrated
Founder & CEO Errik Anderson describes the company's capabilities today and highlights a recent detail to help Voro Therapeutics develop masked T-cell engagers as an example of Alloy's broad capabilities.
Jul 23
From NYSE: Anthropic called out Manifold Bio as a key feedback provider when they announced Claude for life sciences recently. CEO Gleb Kuznetsov explains, and updates us on the brain shuttle program
He describes why Manifold is focused on in vivo work, even to the extent that it is trying to develop a 'virtual organism'. Plus, an update on the brain shuttle program that is partnered with Roche (it is not a transferrin program), and he explains the Anthropic news.
Jul 23
From NYSE: Nabla Bio is using AI and its own dry and wet lab models to discover and develop new antibody and protein based therapeutics. One partner, Takeda, has already come back for more
Co-Founder and CEO Surge Biswas walks us through the platform and describes the type of work that Nabla is doing for partners. Currently, it already has struck deals with Bristol, Astra, and Takeda (twice).
Jul 23
Oxford, UK based Oxford BioTherapeutics has steadily been rolling out new partnerships, most recently with Bristol, Roche, and GSK, for its antibody and target discovery work
CEO Christian Rohlff describes the types of programs Oxford will be collaborating with these companies on, and discussed why the company has prioritized partnerships over an internal pipeline lately. Plus, details on a unique database the company has derived that could lead to even further programs and deals.
Jul 20
Oxford, UK based Sitryx has been busy lately with a deal announced with Boehringer Ingelheim, and its lead program targeting PKM2 in the clinic for atopic dermatitis
CEO Iain Kilty talks about Sitryx's approach to modulating inflammation and shares updates on the Boehringer deal, a program that has been received back from Lilly, and the company's clinical activities.
Jul 20
Oxford, UK based Brainomix has developed an AI based platform that is designed to help hospitals diagnose the existence and severity of strokes from scans quickly as every minute counts
CEO Michalis Papadakis describes the technology and how it has the potential to greatly increase the number of people who experience stroke, and more quickly. The platform is FDA-cleared and CE-marked in Europe, and in wide use in Europe today. The company is also working on a lung fibrosis diagnostic.
Jul 20
Novartis agreed to acquire London based Myricx Bio today for $1.1B up front and up to $400M in milestones. As Myricx's CEO tells us today at the company's HQ, this is all about novel ADC payloads
CEO Mohit Rawat discusses the deal and the scientific rationale for N-myristoyltransferase inhibitor (NMTi) payloads.
Jul 6
Abivax CEO Marc de Garidel discusses freshly released maintenance part 2 results for obefazimod in UC and describes how he believes it builds on initial data announced earlier this month
He discusses learnings from the company's previous data release in early June and how he believes the new data presented gives investors a fuller picture of the efficacy and safety profile of the therapy. He discusses next steps from a regulatory and business standpoint, clarifies a key point of investor confusion, and also provides an update on the company's Crohn's trial.
Jun 30
San Diego based Replicate Bioscience believes that self-replicating RNA (srRNA) has key advantages over linear or circular RNA. Last year Novo signed on as a partner in obesity and diabetes
Co-Founder and CEO Nathaniel Wang describes the biology, which is designed to be more durable, tolerable, and offer less frequent dosing. The lead internal program is a rabies vaccine, and there is early work on mono, RSV/hMPV/PIV, gout, and a cancer vaccine platform. Coverage brought to you by
Jun 26
Recludix will have initial clinical data for its SH2 STAT6 soon (2H 2026) - while it already made waves via a big partnership, a positive profile in humans could signal that SH2's time has arrived
CEO Nancy Whiting walks us through the biology of SH2 and the potential breadth of it as a therapeutics approach (there are 120 SH2 domains). The lead STAT6 program is in healthy volunters, and the company is also working on a BTK. Plus, her thoughts on HHS's new initiative to speed up clinical trials in the United States. Chapters Her thoughts on HHS's new trials initiative - 2:39 Recludix's work on SH2 - 6:51 Coverage brought to you by
Jun 26
While inhibiting the Hedgehog signaling pathway has typically been used in oncology, San Diego based Endeavor BioMedicines has one they believe is well suited for fibrotic diseases like IPF
John Hood, the successful biotech entrepreneur and Co-Founder and CEO of Endeavor, describes the biological hypothesis for Hedgehog inhibition in IPF and why he thinks ENV-101 is the right asset for it. It is currently in a phase 2b that will read towards the end of the year, and he believes the trial can show more than just a slowing of the disease. Coverage brought to you by
Jun 26
San Diego based Origami Therapeutics is developing next-generation protein degraders and correctors for CNS conditions - the lead program is focused on Huntington's disease
Founder & CEO Beth Hoffman describes how Origami's platform is different than other degrades like PROTACs, and how it specifically is designed to clear the mutant huntingtin protein. Plus, details on a global collaboration announced earlier this year with Ipsen. Coverage brought to you by
Jun 26
BIO 2026: Texas based Nanoscope Therapeutics is using optogenetics, or light to turn cells on or off, to try to restore vision for retinal conditions
CEO Sulagna Bhattacharya describes the science behind this, which is gene agnostic, and the work the company is going to develop it and seek approvals both in Japan and the United States.
Jun 26
Actio Biosciences has a precision medicine approach to rare diseases - promising preclinical data in a genetically defined epilepsy has them eagerly awaiting forthcoming clinical results
CEO David Goldstein, a geneticist, describes his frustration with patient care when medicines were lacking rare genetic diseases, and how it motivated him to embark on drug development. Actio's lead program targets KCNT-1 and is in the clinic - preclinical animal work showed that inhibiting the target worked well, and that it may be less of a developmental condition. Coverage brought to you by
Jun 25
Artiva's cell therapy approach to autoimmune conditions is unique because it is NK cell based, donor derived, and there is no engineering of the cells - they believe the benefit is already in the data
CEO Fred Aslan walks us through this unique program and its potential advantages, which include that it can be administered in the community setting and can also be redosed if necessary. A 350 patient randomized registration trial in rheumatoid arthritis will be underway this year. Coverage brought to you by
Jun 25
BIO 2026: AltruBio believes that its PSGL-1, a T-cell checkpoint targeting antibody, could be a "ceiling raiser" in the I&I space
Chair and CEO Judy Chou describes the science behind the target (this is the company's second generation molecule), and discusses the current clinical program in UC. She believes they have a "best in disease outcome" medicine and says they have talked to all the key players in I&I regarding a potential collaboration. Coverage brought to you by
Jun 25
BIO 2026: Kivu Bioscience exited stealth late last year to develop "kinder and gentler" antibody-drug conjugates with a lower antibody to payload ratio to improve precision and tolerability
CEO Mohit Trikha describes the idea behind this approach, which in many ways is the opposite of what many ADC developers have been working on. The lead programs target PTK7 and CEACAM5. Coverage brought to you by
Jun 25
BIO 2026: Nkarta will have key data by the end of the year from its NK cell therapy approach in a host of autoimmune conditions
CEO Paul Hastings describes his opinion of the benefits of an NK cell approach over T-cells, and discusses the work Nkarta has done to get to a high dose that should tell a clear story of the profile of this by year end. Coverage brought to you by
Jun 24
BIO 2026: COUR Pharma last week raised a $50M series B to progress its nanoparticle approach to reprogramming the immune system to treat type 1 diabetes
CEO Dannielle Appelhans describes how the platform works and how the company chose to focus on type 1 diabetes at this time. COUR also has partnerships with Takeda and Genentech. Coverage brought to you by
Jun 24
BIO 2026: Enveda's AI discovery platform leans heavy on chemistry and learnings from Mother Nature - the lead clinical program to come out of it is focused on atopic derm
Founder & CEO Viswa Colluru describes the platform and how he believes it is differentiated from other AI discovery platforms Plus, discussing the lead program and why he believes there is ample room to meet unmet need in the large atopic dermatitis population even with big medicines on the market. Coverage brought to you by
Jun 24
BIO 2026: Vir is scheduled to have its first phase 3 readout in Hepatitis Delta before the end of the year - they believe that their dual mechanism is the difference maker here
President & CEO Marianne De Backer describes the unmet need in Hepatitis Delta and why she believes the dual antibody + siRNA is the right approach in this case. Plus, how investors thing about infectious disease vs oncology. Coverage brought to you by
Jun 24
BIO 2026: The gout market is currently served by two extremes, generic allopurinol in first line and a therapy for extreme refractory cases. Crystalys' experienced team wants to change that
CEO James Mackay describes the company's therapy, dotinurad, which has been approved in Japan since 2020. It is a URAT1 inhibitor, a mechanism that he and his team are very familiar with. Coverage brought to you by
Jun 23
BIO 2026: Rakuten Medical's drug-device 'photoimmunotherapy' is already approved in Japan for head & neck cancer - it is currently in a global phase 3 with an eye on a U.S. approval
COO Abhijit Bhatia describes how it works, and walks us through the design of the phase 3 and Rakuten Medical's global ambitions. Coverage brought to you by
Jun 23
BIO 2026: After presenting updated data at both ASH and EHA, Paris based Enterome is hoping to start a phase 3 for its multi-target peptide immunotherapy in follicular lymphoma
Co-Founder and CEO Pierre Belichard describes the program, which is made up of four synthetic microbial-derived peptides designed to mimic CD20, CD22, CD37 and CD268, and UCP2, and walks us through the recent medical meeting presentations. Plus, Enterome's efforts to get investors or a strategic partner to support the phase 3. Coverage brought to you by
Jun 23
BIO 2026: With two CNS programs in front of FDA and a third that has received breakthrough therapy designation, Praxis Precision Medicines isn't taking its success for granted or slowing down
CEO Marcio Souza walks us through essential tremor and the mechanism of ulixacaltamide, and also comments on a recent seizure trial that did not succeed. Plus, preparing for potential commercial launches and how he thinks about M&A. Coverage brought to you by
Jun 23
.png){kind=logo}